← Eichor
Study identifier: NCT07225712 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia

Condition: Schizophrenia  ·  Sponsor: Otsuka Pharmaceutical Co., Ltd.

PhasePhase 3
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To evaluate the safety of SEP-363856 (75 mg/day or 100 mg/day) administered for 52 weeks in adult participants with schizophrenia

This description comes directly from the study's public registry record.

Talk to the study team

Drug Information Center  ·  +81-3-6361-7314

Always discuss trial participation with your own doctor first.

Locations (1)

Jimbo Kokorono ClinicFukuoka, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07225712